Fundz

Atavistik Bio

Cambridge · Biotechnology, Health Care, Science And Engineering

Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology. Since its inception, Atavistik Bio has rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and tolerability profiles by leveraging the

Key facts

Headquarters
Cambridge
Employees
38
Industries
Biotechnology, Health Care, Science And Engineering
Status
Private
Website
atavistikbio.com
LinkedIn
Company page

Recent activity at Atavistik Bio

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Atavistik Bio funding history

DateRoundAmount
Dec 2025Series B$120.0M
Dec 2023Funding Round$40.0M
Aug 2021Series A$60.0M

Leadership

  • Susan Pandya, Chief Medical Officer
  • Paul Bruno, Chief Business Officer
  • Marion Dorsch, Chief Scientific Officer
  • Bryan Stuart, Chief Executive Officer

Verified email and direct lines for Atavistik Bio’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Atavistik Bio files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Atavistik Bio in the news

Companies similar to Atavistik Bio

  • Nucleai · Biotechnology, Health Care, Science And Engineering, Software
  • Stilla Technologies · Biotechnology, Health Care, Science And Engineering, Software
  • RedHill Biopharma Ltd · Biotechnology, Health Care, Science And Engineering, Software
  • Sequentify · Biotechnology, Health Care, Science And Engineering, Software
  • Zephyr AI, Inc. · Biotechnology, Health Care, Science And Engineering, Software

About Atavistik Bio: questions and answers

What does Atavistik Bio do?

Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology. Since its inception, Atavistik Bio has rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and tolerability profiles by leveraging the

Where is Atavistik Bio headquartered?

Atavistik Bio is headquartered in Cambridge.

How many employees does Atavistik Bio have?

Atavistik Bio has about 38 employees.

Has Atavistik Bio raised funding?

Yes. Fundz has recorded 3 funding events for Atavistik Bio. The most recent, Series B of $120.0M, was in Dec 2025.

Who leads Atavistik Bio?

Bryan Stuart is a Chief Executive Officer at Atavistik Bio.

What is the latest news on Atavistik Bio?

On Sep 25, 2026, Roche enters a research partnership with Atavistik Bio with a USD 70 million upfront payment.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Atavistik Bio across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.